Selective inhibition of gene expression by RNA interference (RNAi) and wider oligonucleotide methods hold the potential to address significant unmet medical needs with importance across major disease areas such as cancer, genetic disorders, cardiovascular disease and autoimmune disorders. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation and positioning in the market place.
This conference offers the opportunity to engage with strategies for advancing RNAi–based therapies for rare and major diseases through devlopment and clinical trials to market, case study updates on approaches to optimising RNAi formulation and delivery and hear lessons learned through successful submissions from regulators.
Electronic Access - Single User Fulfilled By Publisher
CD-ROM Mail Delivery
Electronic Access - Global site License Fulfilled By Publisher